Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Accuri LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner working within 1 distinct art unit. Such a concentrated prosecution profile indicates a singular focus for the company's current patent efforts in this specific technology sector. For the applicant, this concentration means that all resources can be directed toward a single set of claims and a single examining authority, which can lead to a more efficient prosecution cycle.
LAU, JONATHAN S is the busiest examiner for the portfolio, with 1 pending office action under review. As the only examiner involved in the 1 pending office action, Lau represents the entirety of the company's current interaction with the patent office. This allows for a very specific prosecution track within the designated art unit. Practitioners should prioritize understanding the specific preferences of this examiner, as their evaluation will determine the outcome for the entire active portfolio. The administrative requirements are simplified because the company only needs to navigate the procedural culture of one specific division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18522970 | COMPOSITIONS FOR RAISING NAD LEVELS AND METHODS AND USES THEREOF | LAU, JONATHAN S | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18522970 | COMPOSITIONS FOR RAISING NAD LEVELS AND METHODS AND USES THEREOF | LAU, JONATHAN S | 1693 | §102§103 | Non-Final OA | — | Pending | Nov 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAccuri LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonathan S Lau has the most, with 1 of Accuri LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
